188 related articles for article (PubMed ID: 15300145)
21. Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study.
Frantzi M; van Kessel KE; Zwarthoff EC; Marquez M; Rava M; Malats N; Merseburger AS; Katafigiotis I; Stravodimos K; Mullen W; Zoidakis J; Makridakis M; Pejchinovski M; Critselis E; Lichtinghagen R; Brand K; Dakna M; Roubelakis MG; Theodorescu D; Vlahou A; Mischak H; Anagnou NP
Clin Cancer Res; 2016 Aug; 22(16):4077-86. PubMed ID: 27026199
[TBL] [Abstract][Full Text] [Related]
22. Non-invasive diagnostic tests for bladder cancer: a review of the literature.
Bassi P; De Marco V; De Lisa A; Mancini M; Pinto F; Bertoloni R; Longo F
Urol Int; 2005; 75(3):193-200. PubMed ID: 16215303
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer.
Kehinde EO; Al-Mulla F; Kapila K; Anim JT
Scand J Urol Nephrol; 2011 Mar; 45(2):113-21. PubMed ID: 21091091
[TBL] [Abstract][Full Text] [Related]
24. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
25. [Bladder cancer biomarkers].
Dobrowolska-Glazar B; Glazar W; Dobrowolski Z; Lipczyński W
Przegl Lek; 2010; 67(7):479-83. PubMed ID: 21387760
[TBL] [Abstract][Full Text] [Related]
26. Biomarkers for the detection of bladder cancer.
Ross JS; Cohen MB
Adv Anat Pathol; 2001 Jan; 8(1):37-45. PubMed ID: 11152093
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic evaluation of apoptosis inhibitory gene and tissue inhibitor matrix metalloproteinase-2 in patients with bladder cancer.
Eissa S; Shabayek MI; Ismail MF; El-Allawy RM; Hamdy MA
IUBMB Life; 2010 May; 62(5):394-9. PubMed ID: 20408180
[TBL] [Abstract][Full Text] [Related]
28. Urinary markers in the detection of bladder cancer: what's new?
Nielsen ME; Schaeffer EM; Veltri RW; Schoenberg MP; Getzenberg RH
Curr Opin Urol; 2006 Sep; 16(5):350-5. PubMed ID: 16905981
[TBL] [Abstract][Full Text] [Related]
29. [Value of fluorescence in situ hybridization of urine exfoliative cells in diagnosis of urinary bladder neoplasms].
Chen N; Gong J; Zeng H; Wei Q; Zhu YC; Chen M; Zhou Q
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Jan; 42(1):109-13. PubMed ID: 21355314
[TBL] [Abstract][Full Text] [Related]
30. Urine markers for detection and surveillance of bladder cancer.
Xylinas E; Kluth LA; Rieken M; Karakiewicz PI; Lotan Y; Shariat SF
Urol Oncol; 2014 Apr; 32(3):222-9. PubMed ID: 24054865
[TBL] [Abstract][Full Text] [Related]
31. Detection of bladder tumours: role of cytology, morphology-based assays, biochemical and molecular markers.
Eissa S; Kassim S; El-Ahmady O
Curr Opin Obstet Gynecol; 2003 Oct; 15(5):395-403. PubMed ID: 14501243
[TBL] [Abstract][Full Text] [Related]
32. Research progress in potential urinary markers for the early detection, diagnosis and follow-up of human bladder cancer.
Wang HF; Wang JS
Asian Pac J Cancer Prev; 2012; 13(5):1723-6. PubMed ID: 22901111
[TBL] [Abstract][Full Text] [Related]
33. Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer.
Eissa S; Swellam M; Shehata H; El-Khouly IM; El-Zayat T; El-Ahmady O
J Urol; 2010 Feb; 183(2):493-8. PubMed ID: 20006858
[TBL] [Abstract][Full Text] [Related]
34. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
[TBL] [Abstract][Full Text] [Related]
35. [Urine cytology and new markers. Are there any advantages in terms of cost-effectiveness?].
Campodonico F
Urologia; 2013; 80 Suppl 21():7-10. PubMed ID: 23559136
[TBL] [Abstract][Full Text] [Related]
36. The simultaneous use of telomerase, cytokeratin 20 and CD4 for bladder cancer detection in urine.
Siracusano S; Niccolini B; Knez R; Tiberio A; Benedetti E; Bonin S; Ciciliato S; Pappagallo GL; Belgrano E; Stanta G
Eur Urol; 2005 Mar; 47(3):327-33. PubMed ID: 15716196
[TBL] [Abstract][Full Text] [Related]
37. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
[TBL] [Abstract][Full Text] [Related]
38. Diagnosis of bladder cancer using telomerase activity in voided urine.
Cheng CW; Chueh SC; Chern HD
J Formos Med Assoc; 2000 Dec; 99(12):920-5. PubMed ID: 11155745
[TBL] [Abstract][Full Text] [Related]
39. New diagnostic and prognostic tools in bladder cancer.
Tiguert R; Fradet Y
Curr Opin Urol; 2002 May; 12(3):239-43. PubMed ID: 11953681
[TBL] [Abstract][Full Text] [Related]
40. Value of urinary survivin as a diagnostic marker in bladder cancer.
Abd El-Hakim TF; El-Shafie MK; Abdou AG; Azmy RM; El-Naidany SS; Badr El-Din MO
Anal Quant Cytopathol Histpathol; 2014 Jun; 36(3):121-7. PubMed ID: 25141488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]